Welcome to QBiotics

An Australian naturally inspired life sciences company

Human Health
Animal Health
Investor Health

QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®

April, 2020

Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for its lead compound, tigilanol tiglate, with the launch of STELFONTA® in the European markets at the Virbac Oncology Summit Webinar Event (24 April 2020).

STELFONTA® (tigilanol tiglate) is now available as the first pharmaceutical treatment for all grades of canine non-metastatic mast cell tumours (MCT).1 MCTs are the second most frequent cancer diagnosed in dogs and the most common skin cancer, accounting for up to 21% of skin cancer cases.2
 
PDF documentRead the full media release